Results 31 to 40 of about 14,336,962 (399)
Blood, 2017 During the last decade, the development of improved and novel approaches for the treatment of hemophilia A has expanded tremendously. These approaches include factor VIII (FVIII) with extended half-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal ...
P. Lenting, C. Denis, O. Christophe
semanticscholar +1 more source
Research and Practice in Thrombosis and Haemostasis, 2021 The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII products.
Yesim Dargaud +1 more
doaj +1 more source
Haematologica, 2017 Factor VIII C-domains are believed to have specific functions in cofactor activity and in interactions with von Willebrand factor. We have previously shown that factor VIII is co-targeted with von Willebrand factor to the Weibel-Palade bodies in blood ...
Eduard H.T.M. Ebberink +7 more
doaj +1 more source
Attempted spleen transplant in classical hemophilia [PDF]
, 1969 Recent evidence has indicated that the spleen may be partly responsible for synthesis or storage of antihemophilic factor (factor VIII) in dogs (8) and in man (2). Transplantation of the spleen into dogs with congenital deficiency of factor VIII has been
Githens, JH +5 more
core +1 more source
Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII
Journal of Thrombosis and Haemostasis, 2017 Essentials Recombinant factor VIII BAY 94‐9027 conjugates in a site‐specific manner with polyethylene glycol. BAY 94‐9027 was given to patients with severe hemophilia A as prophylaxis and to treat bleeds. BAY 94‐9027 prevented bleeds at dose intervals up
M. Reding +10 more
semanticscholar +1 more source
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors [PDF]
, 2015 In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti-factor VIII antibodies, known as 'inhibitors'.
D'AMICO, Roberto +4 more
core +1 more source
The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces. [PDF]
PLoS ONE, 2015 The factor VIII C2 domain is essential for binding to activated platelet surfaces as well as the cofactor activity of factor VIII in blood coagulation. Inhibitory antibodies against the C2 domain commonly develop following factor VIII replacement therapy
Caileen M Brison +8 more
doaj +1 more source
Scale-factor duality in string Bianchi cosmologies [PDF]
, 1999 We apply the scale factor duality transformations introduced in the context of the effective string theory to the anisotropic Bianchi-type models. We find dual models for all the Bianchi-types [except for types $VIII$ and $IX$] and construct for each of ...
Copeland E. J. +3 more
core +4 more sources
Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor VIII in Mice with Hemophilia A. [PDF]
, 2012 nefficient intracellular protein trafficking is a critical issue in the pathogenesis of a variety of diseases and in recombinant protein production.
Abriss, Daniela +9 more
core +10 more sources
The factor VIII protein and its function.
Acta Biochimica Polonica, 2016 Factor VIII (FVIII), an essential blood coagulation protein, is a key component of the fluid phase blood coagulation system. Human factor VIII is a single chain of about 300 kDa consisting of domains described as A1-A2-B-A3-C1-C2.
A. Mazurkiewicz-Pisarek +3 more
semanticscholar +1 more source